Background: Second-and third-line treatments remain a challenge in advanced colorectal cancer.
Introduction
Leucovorin/5-fluorouracil (LV/5-FU) applied either weekly or every 4 weeks is still considered standard in the first-line treatment of patients with advanced colorectal cancer. However, due to the availability of several new drugs, especially irinotecan and oxaliplatin (L-OHP), the arsenal for the treatment of colorectal cancer has grown considerably. Irinotecan proved to be superior as second-line chemotherapy in patients with 5-FU-resistant disease in terms of progression-free survival and overall survival (OS), when compared with either infusional 5-FU or best supportive care [1] . In first-line chemotherapy, the addition of LV/5-FU to irinotecan significantly improved response rate, median time to progression (TTP) and OS [2] .
Because irinotecan is approved in the United States and Europe for first-line therapy in advanced colorectal cancer, many patients now receive this drug early in the course of treatment, either combined with or after LV/5-FU. Secondand third-line therapy of advanced colorectal cancer in such pretreated patients remains a challenge.
A number of clinical trials have demonstrated synergy between L-OHP and LV/5-FU in patients with tumor progression during or after the same LV/5-FU treatment. Various weekly or bimonthly regimens of high-dose LV/5-FU by continuous infusion combined with L-OHP have been studied in patients who had progressed on an LV/5-FU regimen as firstor second-line treatment. The initial trial using the FOLFOX2 regimen led to a response rate of 46% [3] . This response rate could not be reproduced in subsequent trials using schedules of weekly LV/5-FU plus L-OHP or different variations of the biweekly FOLFOX regimen (FOLFOX3/4/6) [4] [5] [6] [7] [8] [9] . In these trials response rates between 11% and 31%, and a tumor growth control rate [complete response (CR), partial response (PR) and stable disease (SD)] of 42-55% could be obtained. Preliminary data suggest that response rates in patients pretreated with irinotecan and LV/5-FU may be even worse [10] .
Combining heat with antineoplastic drugs has produced suggestive evidence of antitumor synergism. For example, it has been shown that hyperthermia enhances the cytotoxic effect of several drugs, especially of alkylating agents and of platin analogs [11] [12] [13] [14] [15] [16] [17] . Furthermore, hyperthermia can overcome acquired drug resistance [13, 18] . Hyperthermic enhancement of the action of platinum compounds has been shown in vitro. The mechanisms involved include increased DNA adduct formation, decreased adduct removal, a rise in cellular drug accumulation and altered DNA repair. Thermal enhancement, defined as the ratio of the dose causing 99% cell death at 37°C compared with 41°C, was found to be 7.3 for cisplatin and 2.0 for L-OHP, with only a slight (cisplatin) or no (L-OHP) further increase at 43°C [12] . Other effects such as interdependent changes of tumor blood flow, pO 2 and pH, cytokine induction and induction of heat shock proteins (HSP), modulation of the immune system, and enhanced lymphocyte recruitment to tissues may be contributing factors [19] [20] [21] [22] [23] [24] [25] [26] .
A phase I study was initiated to investigate pharmacokinetics and toxicities of whole-body hyperthermia (WBH) (41.8°C) alone, of WBH plus carboplatin (CBDCA) and of CBDCA alone. This study confirmed that the combination improved the therapeutic index without increasing CBDCAinduced myelosuppression [27] , with the latter phenomenon probably being related to cytokine induction. Since this study, a number of phase I-II studies have produced evidence that WBH may be beneficial in combination with chemotherapy [28] [29] [30] [31] .
The WBH program was started at the University Hospital in Hamburg in 1997. Since then >400 treatments have been performed. Considering the known hyperthermic enhancement of L-OHP [12] , it seemed worthwhile to study the potential of WBH in combination with L-OHP in intensively pretreated patients with advanced colorectal cancer. The design of this clinical trial allowed a comparison of the toxicities of chemotherapy alone versus WBH plus chemotherapy within the same patient.
Patients and methods

Patient selection
Eligible patients in the age range 18-70 years had to have a diagnosis of histologically proven adenocarcinoma of the colon or rectum, metastatic disease not amendable by surgery or radiation therapy, a WHO performance status of 0-2, a life expectancy of >3 months, and bidimensionally measurable metastases evaluated by computed tomography (CT) scan. In order to be included, patients had to have progressive disease (PD) as defined by radiological imaging according to WHO guidelines (>25% increase of assessable disease or the appearance of new neoplastic lesions during treatment or within 3 months after completion of previous chemotherapy). Preceding treatment consisted of LV/5-FU 24-h infusion (LV/ 5-FU 24h ), irinotecan in combination with LV/5-FU 24h or irinotecan alone after infusional 5-FU-resistant colorectal cancer. Other eligibility criteria included an adequate bone marrow function (white blood cells >3/nl, absolute granulocyte count >1.5/nl and platelet count >100/nl), adequate liver function (total bilirubin <2 mg/dl), normal coagulation profile, adequate renal function (creatinine <1.5 mg/dl or a creatinine clearance of >30 ml/min and blood urea nitrogen <30 mg/dl) and normal electrolytes. Ineligibility criteria included prior L-OHP-containing therapy, relapse after completing 5-FU-based adjuvant therapy, unresolved bowel obstruction or diarrhea, an allergy to lidocaine or evidence of central nervous system metastasis, a severely compromised respiratory status or documented coronary artery disease, a history of angina pectoris, congestive heart failure or serious dysrhythmias. Table 1 gives the demographic profiles and includes previous therapy of all patients studied.
The ethics committee of our institution approved the protocol. All patients signed a written informed consent before study entry.
Pretreatment evaluation included a complete history and physical examination, a chest X-ray, an abdominal CT and thoracic CT scan if patients had lung metastases. Furthermore, complete pulmonary function tests, ECG, a full chemistry and hematological survey including carcinoembryonic antigen and carbohydrate antigen 19-9 assays were conducted.
Treatment regimen
The regimen consisted of a 2-h infusion of L-OHP 85 mg/m 2 
WBH treatment procedure and timing of chemotherapy
Whole-body hyperthermia was administered by a humidified radiant heat device (RHS-7500; Enthermics Medical Systems, Inc., Menomonee Falls, WI, USA), exposing the patient to a low-density radiant heat while preventing evaporative heat loss. The radiant heat system for delivering WBH has been previously described in detail [32, 33] the only difference being that our system uses an array of thermocabeling instead of a technology using circulating hot water in a cylinder constructed from copper tubing. A hyperthermia treatment session was defined as raising the patient's core temperature to 41.8°C. A typical WBH treatment session lasted ∼3.5-4 h, including a mean of 100 min to reach target temperature, 60 min at 41.8°C and a 1-h cooling period. A 2-h infusion of L-OHP was started when a core body temperature of 39°C had been reached and continued until the end of the target temperature. After L-OHP, folinic acid was infused for 1 h followed by 5-FU for 48 h.
When the target temperature was achieved, the patient was removed from the radiant heat chamber and wrapped in a blanket and a plastic sheet that served as a vapor barrier to prevent heat loss and maintain a stable plateau phase. Esophageal, rectal, skin and ambient air temperatures were monitored continuously using Mallinckrodt temperature probes (Mon-aTherm TM Skin® and Mon-a-Therm Thermistor 400®; Mallinckrodt Medical, Athlone, Ireland) and Enthermics thermometry software. Before each treatment the probes were calibrated against a thermometer standard (accuracy ± 0.02°C). Heart rate, cardiac rhythm, respiratory rate, oxygen saturation and blood pressure were monitored continuously. Urinary output and electrolytes were checked to ensure fluid and electrolyte homeostasis during and after the procedure.
All WBH treatments were performed under general anesthesia. A preceding randomized phase II study had been performed at our institution to identify the most suitable form of anesthesia in this group of patients. Compared with a sedation regimen, general anesthesia proved to be slightly superior regarding oxygen saturation and was less stressful, as shown by a significantly lower increase in the release of adrenaline and noradrenaline. Also, in our experience general anesthesia provided more flexibility regarding the inclusion of patients with less-than-optimal cardiac and pulmonary function. Total intravenous (i.v.) anesthesia was provided with target-controlled propofol infusion, remifentanil and rocuronium. Dopamine, lidocaine and NaCl were administered by continuous infusion to prevent renal malfunction, cardiac dysrhythmias and hypotonic conditions. After induction, the patients were intubated and ventilated with an O 2 /air mixture (FiO 2 >0.4) until they had returned to a core temperature of 39.5°C after the plateau period; i.v. colloid and crystalloid fluids were provided to compensate for fluid loss, and noradrenaline was added when necessary to keep blood pressure within an acceptable range [27] . 
Safety analysis
All patients who had received at least one cycle of L-OHP were evaluated for side-effects. Toxicity was assessed according to WHO criteria [34] except for neurological toxicity and fatigue, which were graded according to an L-OHP-specific scale [35] and to National Cancer Institute common toxicity criteria (NCI-CTC), respectively.
Response analysis
To be eligible for tumor-response assessment, patients had to have measurable disease, and received at least four treatment cycles, including two WBH treatments, except in cases of early clinical disease progression. Patients were evaluated for response based on standard criteria for objective regression of measurable lesions [34] . Computed tomography scan or magnetic resonance imaging assessed the antitumor activity every four cycles or earlier when there was clinical deterioration. Complete response is defined as disappearance of all evidence of tumor previously assessed without the development of new malignant lesions lasting for at least 4 weeks. Partial response refers to a >50% decrease in tumor size lasting for at least 4 weeks without the appearance of new lesions. Stable disease is considered to be a <50% regression of measurable disease and a <25% progression of measurable disease lasting for at least 8 weeks, whereas progressive disease is a >25% increase in the size of lesions present at the start of therapy or appearance of new metastatic lesions. Time-to-progression and OS were calculated from the beginning of treatment containing L-OHP until disease progression or death, respectively.
Statistical planning and analysis
Sample size was determined according to the optimal two-stage design for phase II studies proposed by Simon [36] . The study was designed for two strata, thus allowing for a separate analysis of the two subgroups of patients pretreated with irinotecan alone or combined with LV/5-FU 24h , and those pretreated with LV/5-FU 24h only. In each subgroup the null hypothesis tested was a true response probability of <10% (α = 10%). The stratum-specific alternative hypothesis was a true response rate of at least 30%. If the specified alternative hypothesis was true, the probability of rejecting further studies was limited to β = 5%. Based on these criteria, the design required a sample size of n = 33 patients in each subgroup. The first stage consisted of n = 26 patients in each group. If the number of responses was less than four, the trial could be terminated in the specific subgroup. Otherwise, data acquisition had to be continued. If the number of responses after the second stage exceeded five, the group-specific null hypothesis could be rejected.
Nominal and ordinal parameters were analyzed via absolute and relative frequencies. For response rates, exact two-sided 95% ClopperPearson confidence intervals are presented. Kaplan-Meier methods were applied for 'time to failure' variables. Median progression-free survival, and median OS times are presented with their 95% confidence intervals (CI). In addition, 1-year survival rates were calculated.
In addition, toxicity was analyzed on a per-patient basis by calculating the cumulative toxicity, which was defined as the worst toxicity grade observed during therapy.
Results
From January 1999 to January 2001, 44 patients were enrolled. Table 1 outlines the patients' characteristics. Thirtytwo patients (73%) had previous definitive surgery; in the adjuvant setting 17 patients (39%) had received prior 5-FUcontaining chemotherapy and six patients (17%) had received radiation therapy. A total of 20 patients (45%) were symptomatic at baseline. The most common symptom was pain related mainly to the hepatic and bone metastases. All patients had been treated previously for metastatic disease. Twentyfive patients (57%) had proof of disease progression while on therapy. The remaining 19 patients had SD but progressed within 3 months of completion of therapy. Of the 41 patients evaluated for response, 16 had received 5-FU-containing chemotherapy in the adjuvant setting. For metastatic disease, seven patients were pretreated with LV/5-FU 24h alone, and 34 patients were pretreated with LV/5-FU 24h and irinotecan, given either sequentially (eight patients) or simultaneously (25 patients). Nineteen patients had received one and 22 patients had received two previous regimens.
Due to slow recruitment of patients pretreated with LV/ 5-FU 24h alone, this stratum had to be closed after the inclusion of eight patients. Subsequently, antitumor activity was assessed for the group as a whole and separately for the patients pretreated with LV/5-FU 24h and irinotecan.
All 44 patients were included in the safety analysis. Fortyone patients met all eligibility criteria and were included in the efficacy analysis.
Extent of exposure and safety
A total of 273 cycles were administered, 130 with and 143 without WBH. The mean dose intensity per cycle was 82 mg/m 2 for L-OHP (96.5% of the planned dose) and 3 g/m 2 (100% of the planned dose) for 5-FU. The average number of treatment courses was six (range two to twelve). Overall, patients tolerated the therapy fairly well. Grade III toxicity was rare and evenly balanced between cycles given with or without WBH. Treatment-related prolongation of therapyfree intervals occurred in 8% of cycles with and 10% of cycles without WBH, with an apparent relationship to the number of preceding cycles. Common toxicities per patient and per cycle are reported in Tables 2 and 3 . L-OHP-induced neurosensory toxicities were the most frequent side-effects. Sixty-eight percent of patients reported some symptoms of neuropathy, which were usually mild using the L-OHP-specific scale [35] . Only one patient developed severe sensory neuropathy with functional impairment due to a loss of sensitivity in the fingertips and soles of the feet towards the end of the therapy. Interestingly, almost all patients reported neurotoxicity to be less pronounced in cycles combined with WBH as compared with those given without WBH. Other neurological events included one episode each of a general and focal convulsive attack occurring during WBH treatment. The most common acute adverse events, easily controlled with loperamide and anti-emetics, were grade 1 and 2 diarrhea and nausea/vomiting. Grade 3 diarrhea was rare, affecting only two patients. Severe (grade 3) neutropenia and thrombocytopenia were uncommon (two patients). One patient died of sepsis and pneumonia following WBH. In this patient the WBH treatment was well tolerated. Three days after WBH the patient developed pneumonia and demonstrated a significant increase in lactate dehydrogenase; thus a tumor lysis syndrome was suspected. The patient died 4 days later.
Toxicity related to WBH included 17 episodes of mucosal herpes infection, readily responsive to aciclovir, with a history of mucosal herpes infection being identified as a risk factor in all these patients. We observed only two such episodes in cycles applied without WBH. Pressure sores (WHO grade 1 and 2) developed in three patients, in two cases at the heels and in one case near the tip of the finger, where the measurement of oxygen saturation had been performed using a finger clip. A fatigue syndrome grade 3 and 4 according to NCI-CTC criteria was more often seen in cycles applied with WBH than without (20% and 6% versus 5% and 3%, respectively). We observed five episodes of transient cardiac arrhythmias and electrocardiographic signs of myocardial ischemia in five patients (WHO grade 3). All episodes occurred during the first WBH treatment at temperatures >41°C and resolved quickly after lowering the patient's core temperature. To exclude underlying coronary artery disease, further diagnostic (myocardial perfusion imaging under stress) was performed in four patients with negative results. Treatment was continued in these patients, and further WBH showed no cardiac problems. One patient rejected further testing and had to be excluded from the study. Two patients could not receive a second WBH treatment, one because of acute heart failure (WHO grade 3) in the treatment-free interval following the first WBH treatment and the other due to problems following esophageal intubation before the second WBH treatment. Thus, in accordance with response analysis criteria these three patients were not eligible for response. Side-effects Grade (23) 22 (50) 11 (25) 1 (2) 0 (0) 
Antitumor activity
The overall response rate (CR and PR) for the 41 patients evaluable for efficacy was 20% (95% CI 9% to 35%) with two CRs and six PRs. In addition, 23 patients (56%) had SD and nine (22%) had PD, thus tumor growth control was achieved in 76% of cases. With a median observation time of 70 weeks (range 22-125 weeks), the median TTP was 21 weeks (95% CI 17-25 weeks). The median OS since the start of protocol treatment was 50 weeks (95% CI 39-61 weeks). The two CRs lasted for 32 and 62+ weeks. One early death occurred due to sepsis and tumor lysis.
The crude Kaplan-Meier-estimated probability of 1-year survival was 46%.
No substantial differences in response rates were observed between the subgroups of patients who developed PD while receiving therapy and those who progressed within 3 months after completing prior chemotherapy.
Discussion
In concordance with earlier reports, the study confirmed that the use of radiant heat provides a relatively non-toxic mode for the application of WBH [27, 28, 30, 31] . No WHO grade 4 toxicities were observed. Whole-body hyperthermia is undoubtedly associated with cardiac stress. Heart rate and cardiac output are known to increase significantly with rising core temperature [32] . Cardiac arrhythmias may occur despite strict exclusion criteria regarding a history of coronary artery disease or dysrhythmias. This underlines the necessity for continuous cardiac monitoring during WBH treatment. An increased incidence of oral herpes simplex in conjunction with WBH has been described previously [27, 28, 31] . Although this has been associated with the administration of ondansetron [27] , the nature of this observation clearly requires further investigation. The increased incidence of fatigue observed after WBH cycles is most likely a consequence of the combination of general anesthesia, heat exposure and chemotherapy.
Interestingly, there was no evidence of a hyperthermiainduced enhancement of known drug-related hematological and gastrointestinal toxicities, despite the fact that in vitro data have demonstrated a clear thermal enhancement of cytotoxicity for L-OHP [12] . In this context, it is worth mentioning that the addition of WBH to CBDCA has been shown to reduce myelosuppression in an earlier trial [27] . It was speculated that this observation was possibly due to a WBHinduced, but short-lived increase in the production of different cytokines including granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor (GM-CSF) [20, 21] .
The majority of patients had been pretreated with LV/5-FU by continuous infusion plus irinotecan. Results presented here suggest that L-OHP/LV/5-FU combined with WBH is active in this group of patients. A tumor growth control (CR, PR or SD) in 76% of patients and a TTP of 21 weeks were obtained. These data compare favorably with the activity of similar regimens in less extensively pretreated patients treated with biweekly [8, 9, 37] or weekly schedules [5] [6] [7] . The efficacy of L-OHP/LV/5-FU in patients pretreated not only with LV/ 5-FU but also with irinotecan has not been studied in larger trials. Preliminary data indicate an even smaller clinical benefit in this group of patients [10] . Yet, a meaningful comparative analysis of the trials mentioned above is impaired by inconsistent inclusion criteria. Some trials allowed inclusion of patients who had disease progression while on different LV and 5-FU regimens, a treatment-free interval for metastatic disease of <6 months, or a relapse within 6 months after completing 5-FU-based adjuvant treatment [7, 9, 37] . Others included only fully refractory patients [6, 8, 10] .
One can only speculate on the contribution of WBH to conventional chemotherapy. A hyperthermic enhancement of L-OHP may play a role. This hypothesis is supported by in vitro data demonstrating a clear relationship between response and length of exposure and concentration for L-OHP in different tumor cell lines [38] . Furthermore, several publications suggest that L-OHP dose escalation provides a significant advantage in terms of response rate and progression-free survival in patients with advanced colorectal cancer [4, [39] [40] [41] . In these trials, WHO grade 3-4 neutropenia was observed in up to 39% of patients. This was not attributed to high L-OHP dose intensity but rather to 5-FU [39] . In our trial, we did not observe a single episode of WHO grade 4 neutropenia or thrombocytopenia.
Hyperthermia is known to induce a complex immune response, which is in part mediated by cytokine release, including interleukin (IL)-1β, IL-6, IL-8, IL-10 and tumor necrosis factor-α peripherally [20, 42] , and at the level of the bone marrow, IL-3 and GM-CSF [21] . In our patients, we found evidence for a prolonged T-cell activation suggested by an increase of CD69 and the soluble IL-2 receptor, both known as T-cell activation markers and an increase of the number of cytotoxic T cells following WBH treatment [26] . The early activation of heat shock genes encoding the preferential synthesis of hsp is part of the 'thermal stress response' [43] . Members of different HSP families (e. g. hsp70, hsp90-related glycoprotein gp96) most probably play a role in the stimulation of the immune response, and it has been shown that the HSP chaperon the antigenic repertoire of the cells from which they are purified [44, 45] . Furthermore, the heatinducible hsp70 is expressed on the cell surface of certain tumor cells and acts as a recognition signal for natural killer cells [22, 46] . Enhanced L-selectin-dependent adhesion of lymphocytes to vascular endothelium with the consequence of increased lymphocyte recruitment to tissues has been shown following fever-range hyperthermia [24, 25] . Whether and to what extent these factors contribute to the results of this study is not yet clear. As mentioned already, the design of our study does not allow us to answer the question of whether WBH has a beneficial therapeutic effect. Therefore a phase III study has been initiated to compare the chemotherapeutic regimen as presented in this paper with and without WBH. We will continue to apply WBH to every second treatment cycle only, since we believe that due to the need for general anesthesia a biweekly exposure to WBH would not be feasible.
